Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Radiation Oncology
•
Genitourinary Cancers
•
Prostate Cancer
•
Medical Oncology
•
Urologic Oncology
Which patients do you consider to be good candidates for salvage local treatment after radiation therapy?
How does time since radiation, original PSA and grade group/gleason score inform your decision?
Related Questions
In a patient with very high risk prostate cancer opting for prostatectomy, when, if ever, do you recommend neoadjuvant ADT?
Do you still order mpMRI for staging of prostate cancer in addition to PET-PSMA?
How aggressive would you be in irradiating asymptomatic bone metastases in a patient with metastatic prostate cancer?
Can you/do you use an androgen receptor blocker alone in patients with metastatic hormone-sensitive prostate cancer who cannot tolerate GnRH-directed therapy?
Would you treat the prostate in a patient with widely metastatic disease who has CR to all metastatic sites after systemic therapy or ADT?
How do you interpret PSMA/PET with focal prostate activity after XRT currently on ADT with stable PSA?
Is it appropriate to offer definitive trimodality therapy, as an equivalent option to neoadjuvant chemotherapy followed by radical cystectomy, in patients with muscle-invasive bladder cancer regardless of fitness or platinum eligibility?
Do you ever initiate on degarelix and then switch to leuprolide for patients with prostate cancer and cardiac risk factors receiving ADT?
How do you sequence Ra-223 and Lu-177 in patients with mCRPC with predominantly bony disease?
How do you reconcile discrepancies in clinical prostate cancer staging with AJCC and NCCN?